North Dakota Clinical Trials Report — July 2026

North Dakota residents considering a clinical trial should act promptly: 8 recruiting studies are projected to close within the next 90 days, including 2 that accept healthy volunteers. Screening and site appointments can take time, so people who may qualify should contact study teams now rather than waiting for the listed closing window.

The state currently has 213 recruiting trials across 7 cities and 85 research sites. July brought only 1 new study, down from 6 in both May and June, making the month’s new opening more focused than usual: an industry-sponsored Phase 2 drug study for moderate-to-severe atopic dermatitis.

A Phase 2 eczema study is July’s key new opportunity

Inmagene LLC opened NCT07734415, “Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis.” The Phase 2 trial plans to enroll 400 participants and will evaluate the safety and efficacy of longer-term treatment with IMG-007 in people with moderate-to-severe atopic dermatitis.

The study is recruiting in Fargo, the only North Dakota city identified with a new trial this month. It is a drug intervention and is sponsored by Inmagene LLC, placing July’s new activity entirely within industry-sponsored research. The trial does not accept healthy volunteers, so applicants will need to meet the study’s disease-related requirements.

• NCT07734415 — Phase 2 long-term safety and efficacy study of IMG-007 for moderate-to-severe atopic dermatitis.
• New condition groupings this month — atopic dermatitis, atopic dermatitis eczema, and eczema.
• Location — Fargo, the only city with a new North Dakota trial in July.

Although the condition labels overlap, they reflect the month’s narrow clinical focus rather than three separate new studies. People with moderate-to-severe atopic dermatitis should review the eligibility criteria and ask the Fargo site whether recruitment and screening appointments remain available.

Closing studies span cancer and cardiometabolic disease

The eight trials approaching closure cover a wide range of conditions, with cancer-related studies making up most of the listed categories. The closing-soon portfolio includes studies involving lung cancer, malignancy, malignant solid neoplasms, multiple myeloma, metastatic small intestinal adenocarcinoma, stage III and stage IIIA small intestinal adenocarcinoma, and peritoneal malignant mesothelioma. One study addresses cardiometabolic disease, and another focuses on nonsegmental vitiligo.

• Cardiometabolic disease — 1 closing-soon trial.
• Lung cancer, at diagnosis — 1.
• Malignancy and malignant solid neoplasm — 1 each.
• Metastatic small intestinal adenocarcinoma — 1.
• Multiple myeloma — 1.
• Nonsegmental vitiligo — 1.
• Peritoneal malignant mesothelioma — 1.
• Stage III and stage IIIA small intestinal adenocarcinoma — 1 each.

The available data do not identify individual NCT numbers for these closing studies, but the disease categories provide a practical starting point for patients and caregivers searching the state’s recruiting listings. People with a relevant cancer diagnosis, multiple myeloma, vitiligo, or cardiometabolic disease should verify the current enrollment status directly and ask how much time remains for screening.

Healthy-volunteer opportunities remain limited

None of July’s new studies accept healthy volunteers, while 18 healthy-volunteer trials are recruiting statewide overall. Two of the 8 studies closing within 90 days accept healthy volunteers, creating a particularly time-sensitive opportunity for people without a diagnosed condition.

Healthy adults should search the current statewide listings rather than rely only on July’s new-trial announcements. Because two suitable studies may close soon, prospective volunteers should confirm age, medication, travel, and visit requirements as soon as possible. The available eligibility data show that 0 new trials are specifically limited to women, 0 are specifically limited to men, and 0 include children. One new study includes older adults in its eligibility criteria.

For patients, the most immediate action is different: people with the conditions represented among the closing studies should begin with those listings, while people with moderate-to-severe atopic dermatitis should also examine NCT07734415 in Fargo. Eligibility is determined by each study team, and a condition label alone does not guarantee qualification.

Fargo leads July, while statewide access remains broader

Fargo is the only city with a new trial this month, but North Dakota’s overall recruiting activity extends across 7 cities and 85 research sites. The statewide totals indicate that opportunities are not confined to the July opening in Fargo. However, the data do not provide a city-by-city breakdown of the 213 active trials, so they cannot establish whether most studies cluster in Fargo or another metropolitan area.

People should search by both location and condition. A trial may list several research sites across the state, while a highly specialized cancer or dermatology study may have only one local location. Residents outside Fargo may need to discuss travel, visit frequency, and whether any assessments can be completed remotely before pursuing screening.

July continues a sharp slowdown in new openings

North Dakota’s six-month trend shows a fluctuating but marked decline in July activity. The state recorded 4 new trials in February, 1 in March, 3 in April, 6 in May, 6 in June, and 1 in July.

• February 2026 — 4 new trials.
• March — 1.
• April — 3.
• May — 6.
• June — 6.
• July — 1.

That slowdown makes the closing-soon listings especially important for people seeking an immediate opportunity. At the same time, the Inmagene study gives dermatology patients a new option to investigate, particularly those living near Fargo or able to travel there. As the second half of 2026 progresses, recruitment may shift again as existing studies close and additional trials appear in North Dakota’s research sites.